Evaluation of the Glycine Transporter Inhibitor Org 25935 as Augmentation to Cognitive-Behavioral Therapy for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Journal of Clinical Psychiatry

Volumn 73, Issue 5, 2012, Pages 647-653

  Nations, Kari R ^a   Smits, Jasper A J ^b   Tolin, David F ^c   Rothbaum, Barbara O ^d   Hofmann, Stefan G ^e   Tart, Candyce D ^b   Lee, Allen ^a   Schipper, Jacques ^f   Sjogren, Magnus ^f   Xue, Dixi ^a   Szegedi, Armin ^a   Otto, Michael W ^e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SOUTHERN METHODIST UNIVERSITY   (United States)

^c INSTITUTE OF LIVING   (United States)

^d EMORY UNIVERSITY   (United States)

^e BOSTON UNIVERSITY   (United States)

^f Merck Sharp and Dohme   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; GLYCINE TRANSPORTER 1; N METHYL N [[1,2,3,4 TETRAHYDRO 6 METHOXY 1 PHENYL 2 NAPHTHALENYL]METHYL] GLYCINE; ORG 25935; PLACEBO; PROTEIN INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; AGORAPHOBIA; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PANIC; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT DURATION; VERTIGO; VISUAL IMPAIRMENT;

EID: 84861816137     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07081     Document Type: Article

References (52)

1. Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008;69(4):621-632. PubMed (Pubitemid 351792338)
2. Otto MW. Learning and "unlearning" fears: preparedness, neural pathways, and patients. Biol Psychiatry. 2002;52(10):917-920.doi:10.1016/S06- 323(02)01719-5 PubMed (Pubitemid 35363292)
3. Otto MW, Smits JA, Reese HE. Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry. 2004;65(suppl 5):34-41. PubMed
4. Anderson KC, Insel TR. The promise of extinction research for the prevention and treatment of anxiety disorders. Biol Psychiatry. 2006;60(4):319-321.doi:10.1016/j.biopsych.206.06.02 PubMed (Pubitemid 44215858)
5. Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry. 2007;12(2):120-150.doi:10.1038/sj.mp.401939 PubMed (Pubitemid 46160979)
6. Morris RG. Synaptic plasticity and learning: selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor antagonist AP5. J Neurosci. 1989;9(9):3040-3057. PubMed (Pubitemid 19260822)
7. Bliss TVP, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361(6407):31-39.doi:10.1038/ 361031a0 PubMed (Pubitemid 23020772)
8. Falls WA, Miserendino MJ, Davis M. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci. 1992;12(3):854-863. PubMed
9. Davis M, Ressler K, Rothbaum BO, et al. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60(4):369-375.doi:10.1016/j.biopsych.206.03.084 PubMed (Pubitemid 44215855)
10. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11):1136-1144.doi: 10.101/archpsyc.61.1.136 PubMed (Pubitemid 39463415)
11. Otto MW, Tolin DF, Simon NM, et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010;67(4):365-370.doi:10.1016/j.biopsych.209.07.036 PubMed
12. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63(6):544-549.doi:10.1016/j.biopsych.207.1.01 PubMed
13. Hofmann SG, Meuret AE, Smits JAJ, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63(3):298-304.doi:10.101/archpsyc.63.3.298 PubMed (Pubitemid 43345354)
14. Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007;62(8):835-838. doi:10.1016/j.biopsych.206.12.020 PubMed (Pubitemid 47488217)
15. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165(3):335-341, quiz 409.doi:10.176/api.ajp.207.0705076 PubMed
16. Storch EA, Murphy TK, Goodman WK, et al. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010;68(11):1073-1076.doi:10. 1016/j.biopsych.2010.07.015 PubMed
17. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118-1126.doi:10.1016/j.biopsych.208.01.012 PubMed
18. Hofmann SG. Enhancing exposure-based therapy from a translational research perspective. Behav Res Ther. 2007;45(9):1987-2001.doi:10.1016/j.brat. 207.06.06 PubMed (Pubitemid 47210960)
19. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571-1575. PubMed (Pubitemid 27471351)
20. Laube B, Hirai H, Sturgess M, et al. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron. 1997;18(3):493-503.doi:10.1016/S0896-6273(0)81249- 0 PubMed (Pubitemid 27138796)
21. Aragón C, López-Corcuera B. Structure, function and regulation of glycine neurotransporters. Eur J Pharmacol. 2003;479(1-3):249-262. doi:10.1016/j.ejphar.203.08.074 PubMed (Pubitemid 37377893)
22. Aragón C, López-Corcuera B. Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion. Trends Pharmacol Sci. 2005;26(6):283-286.doi:10.1016/j.tips.205.04.07 PubMed (Pubitemid 40733520)
23. Eulenburg V, Armsen W, Betz H, et al. Glycine transporters: essential regulators of neurotransmission. Trends Biochem Sci. 2005;30(6):325-333.doi:10. 1016/j.tibs.205.04.04 PubMed (Pubitemid 40799051)
24. Chen L, Muhlhauser M, Yang CR. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol. 2003;89(2):691-703.doi:10.152/jn.0680.202 PubMed (Pubitemid 36206118)
25. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem. 2006;97(6):1611-1626.doi:10.1/j.1471-4159. 206.0391.x PubMed (Pubitemid 43873656)
26. Boulay D, Pichat P, Dargazanli G, et al. Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav. 2008;91(1):47-58.doi:10.1016/j.pb.208.06.09 PubMed
27. Shimazaki T, Kaku A, Chaki S. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl). 2010;209(3):263-270.doi:10.107/s0213-010-1794-y PubMed
28. Depoortère R, Dargazanli G, Estenne-Bouhtou G, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology. 2005;30(11):1963-1985.doi:10.1038/ sj.np.13072 PubMed (Pubitemid 43093498)
29. Hashimoto K, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol. 2008;18(6):414-421.doi:10.1016/j.euroneuro.207.07.09 PubMed (Pubitemid 351608551)
30. Walker GB, Hamilton W, Ge J, et al. Org 25935: a selective glycine uptake inhibitor. Schizophr Res. 2001;49(suppl 1):97.
31. Lidö HH, Stomberg R, Fagerberg A, et al. The glycine reuptake inhibitor org 25935 interacts with basal and ethanol-induced dopamine release in rat nucleus accumbens. Alcohol Clin Exp Res. 2009;33(7):1151-1157.doi:10.1/j. 1530-027.209.0938.x PubMed
32. Ge J, Hamilton W, Shahid M, et al. The effects of Org 25935 on the extracellular levels of glycine in brain regions of freely moving rats using microdialysis. Br J Pharmacol. 2001; 133: 135P.
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Press; 2000.
34. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222.
35. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
36. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/PSY SCREEN). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
37. Santini E, Muller RU, Quirk GJ. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci. 2001;21(22):9009-9017. PubMed (Pubitemid 33054862)
38. Shear MK, Rucci P, Williams J, et al. Reliability and validity of the Panic Disorder Severity Scale: replication and extension. J Psychiatr Res. 2001;35(5):293-296.doi:10.1016/S02-3956(01)028-0 PubMed (Pubitemid 32928431)
39. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.doi:10.1/j.204-8341.1959.tb0467.x PubMed
40. Shear MK, Vander Bilt J, Rucci P, et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety. 2001;13(4):166-178.doi:10.102/da.103 PubMed (Pubitemid 32550226)
41. Reiss S, Peterson RA, Gursky DM, et al. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther. 1986;24(1):1-8.doi:10.1016/05-7967(86)90143-9 PubMed (Pubitemid 16207745)
42. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326. PubMed (Pubitemid 23311543)
43. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract. 2005;12(1):72-86. doi:10.1093/clipsy.bpi09 (Pubitemid 40309355)
44. Myers KM, Carlezon WA Jr, Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology. 2011;36(1):274-293.doi:10.1038/np.2010.8 PubMed
45. Perry KW, Falcone JF, Fell MJ, et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs cortical brain areas. Neuropharmacology. 2008;55(5):743-754.doi:10.1016/j.neuropharm.208.06.016 PubMed
46. Chen RQ, Wang SH, Yao W, et al. Role of glycine receptors in glycineinduced LTD in hippocampal CA1 pyramidal neurons. Neuropsychopharmacology. 2011; 36(9):1947-1958. doi: 10.1038/np.201.86 PubMed
47. Balakrishnan V, Kuo SP, Roberts PD, et al. Slow glycinergic transmission mediated by transmitter pooling. Nat Neurosci. 2009;12(3):286-294.doi:10.1038/n. 265 PubMed
48. Modi ME, Young LJ. D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. Biol Psychiatry. 2011;70(3):298-304.doi:10.1016/j.biopsych.201.01.026 PubMed
49. Butler AC, Chapman JE, Forman EM, et al. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006;26(1):17-31.doi:10.1016/j.cpr.205.07.03 PubMed (Pubitemid 41803609)
50. Clark DM, Salkovskis PM, Hackmann A, et al. Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol. 1999;67(4):583-589.doi:10.1037/02-06X.67.4.583 PubMed (Pubitemid 29379473)
51. Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry. 2005;62(3):290-298.doi:10.101/archpsyc.62.3.290 PubMed (Pubitemid 40990974)
52. Otto MW, Tolin DF, Nations KR, et al. Five sessions and counting: considering ultra-brief treatment for panic disorder. Depress Anxiety. In press.